Neobiosis, LLC
🇺🇸United States
Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS).
Phase 1
Not yet recruiting
- Conditions
- Neurological ComplicationPost-Acute COVID-19 SyndromeCognitive Impairment
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Neobiosis, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT05947617
© Copyright 2025. All Rights Reserved by MedPath